Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1989-09-13
1991-07-02
Hollrah, Glennon H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514 12, 514930, 424 852, 424 855, 424 851, A61K 31195, A61K 455, A61K 3766, A61K 3710
Patent
active
050286277
ABSTRACT:
A method for prophylaxis of treatment of an animal for systemic hypotension induced by internal nitrogen oxide production. The method involves administering a therapeutically effective amount of certain arginine derivatives to inhibit nitrogen oxide formation from arginine. Preferaby N.sup.G -substituted arginine or an N.sup.G,N.sup.G -disubstituted arginine (having at least one hydrogen on a terminal guanidino amino group replaced by another atomic species) is administered to an animal possibly developing or already having induced systemic hypotension. The arginine derivatives are preferably of the L configuration and include pharmaceutically acceptable addition salts. Prophylaxis or treatment or systemic hypotension in a patient which has been induced by chemotherapeutic treatment with biologic response modifiers such as tumor necrosis factor or interleukin-2 may be accomplished. Treatment of an animal for systemic hypotension induced by endotoxin, i.e., septic shock may also be accomplished by treatment with the arginine derivatives.
REFERENCES:
patent: 4282217 (1981-08-01), Baglioni et al.
Palmer, R. M. J. et al. (Jun. 30, 1988) L-Arginine is the Physiological Precursor for the Formation of NO in EDR. Biochem. Biophis Res. Commun 153(3) 1251-1256.
Stuehr, D. J. et al. (1987) Induction of NO.sub.2 /NO.sub.3 Synthesis in Murine Macrophages by BCG Infection, Lymphokines or Interferony J. Immonol 139:518-525.
Schmidt, H. H. H. W. et al. (1988) Arginine is a Physiological Precursor of Endotherlium Derived NO Eur. J. Pharmacol. 154:213-216.
Stuehr, D. J. et al., J. Exp. Med. vol. 169 (1989), 1011-1020.
Aisaka, K. et al., Biochem. Biophys. Res. Commun., vol. 160 (1989) 881-886.
Rees, D. D. et al., Proc. Natl. Acad. Sci. U.S.A., vol. 86 (1989) 3375-3378.
Iyengar, R. et al., Proc. Natl. Acad. Sci. U.S.A., vol. 84, (1987), 6369-6373.
Palmer, R. M. J. et al., Nature, vol. 333 (1988) 664-666.
Stuehr, D. J. et al., Biochem. Biophys. Res. Commun., vol. 161 (1989) 420-426.
Turan, A. et al., Acta Chimica Academiae Scientiarum Hungaricae, Tomas 85 (1975) 327-332.
Griffith Owen W.
Gross Steven
Kilbourn Robert G.
Levi Roberto
Board of Regents , The University of Texas System
Cornell Research Foundation Inc.
Hollinden Gary E.
Hollrah Glennon H.
LandOfFree
Method of using arginine derivatives to inhibit systemic hypoten does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using arginine derivatives to inhibit systemic hypoten, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using arginine derivatives to inhibit systemic hypoten will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1247570